Mahendra Rao, with co-moderator George Martin, led this live discussion on 30 March 2004. Readers are invited to submit additional comments by using our Comments form at the bottom of the page.
Dr. Mahendra Rao led this live discussion with co-moderator George Martin on 30 March 2004.
Participants: Mahendra Rao, National Institutes of Health, Baltimore, Maryland; George Martin, University of Washington, Seattle, Washington; Joy Snider, Washington University School of Medicine, St. Louis, Missouri; Jeanne Loring, ARCGEN, San Diego, California; Dan Freudenberger, Neurobiology Council, Harvard Medical School; Jim Tretheway, HDSA-Wisconsin Director, Wisconsin; June Kinoshita, ARF; Greg Brewer, Southern Illinois University; Kirk Townsend, University of South Florida; Danielle Regan, American University, Washington; Adrian Isaacs; Richard Lipsius; Franz-Josef Mueller; Angela Biggs.
Note: The transcript has been edited for clarity and accuracy.
I wanted to point out that while stem cells offer hope, there are several important issues that must be considered when assessing the utility of stem cells, but which have been ignored.
Dr. Rao, Yes, indeed. It is time for reality testing! I wonder if you could begin with your definitions of a stem cell, progenitor cells?
A stem cell is a cell that has the capability of self-renewing over a prolonged time period and can generate multiple phenotypes in response to an exogenous signal. A progenitor cell is more restricted in its differentiation capability and undergoes only limited self-renewal (perhaps by symmetric division). The most important question, of course, is are there stem cells in the adult brain and are their number reasonable to consider clinical therapy of whatever form.
Dr. Rao, thanks for these clear definitions. I could perhaps add some further definitions that sometimes cause confusion. No stem cell seems to be truly totipotent, as they cannot make trophoblast. Embryonic stem cells are pluripotent, while I regard embryonic carcinoma cells as merely multipotent (which includes capability of some neural differentiation).
Agreed. Indeed, stem cells should be classified based on their differentiation bias. ES, tissue specific, etc. Does anyone have a comment on the statement that in the adult, neural stem cells are restricted to limited regions of the brain?
The evidence that stem cells are present in the adult brain seems solid, and they can differentiate into neurons and other cell types. But what is the status of the data suggesting that they can play a functional role, or potentially replace cells damaged in neurodegenerative disorders?
Joy, the evidence is solid. It's the numbers I am concerned about. I also am concerned about the transdifferentiation potential of hematopoietic stem cells (HSCs). The numbers of cells in the human brain that appear to be stem cells is small. In many regions, when stem cells are transplanted, they don't become neurons, and it appears that the hippocampus is perhaps the only really neurogenic region.
I was just wondering about the status of studies on functional integration of the endogenous stem cells—I know there is some data out there, but not much last time I checked.
Joy, you are correct. We need a lot more information on that point.
Dr. Rao, are you as depressed as I am about those two Nature papers that just came out showing a failure of bone marrow hematopoietic progenitor cells to differentiate into myocardial cells in ischemic hearts? One was from my colleague Chuck Murry (see Murry et al., 2004), and the other involved Irv Weissman (see Balsam et al., 2004).
As Dr. Martin pointed out, the functional integration data that looks really good is mostly from neural cells, and generally only in regions of ongoing neurogenesis as far as neuronal integration is concerned.
Mahendra, does your comment suggest that there is some kind of region-specific signal that enables functional integration to occur? If so, what might that be?
Yes. Multiple lines of evidence suggest that cell-intrinsic and cell-extrinsic signals coordinate to direct site-specific integration. These vary in different regions.
In light of the Parkinson's graft trials (Freed, et al., 2003), what do you think we need to do to control expression or overexpansion of the graft?
Hello, Greg. I am not quite sure which problem you are referring to—perhaps the Freed results? But the general answer, I think, is that we need to know how to control cells, and this knowledge is rapidly being acquired.
Yes, if neural stem cells can be introduced into the Alzheimer's disease brain, what are its prospects in the context of the underlying pathology—amyloid deposition, inflammation, etc.?
This is an unknown, Kirk, but in general, cells, particularly healthy cells, seem to survive in an inflamed environment. The best data has come from stroke and injury models.
Kirk, I am not optimistic about the clinical applications of the introduction of stem cells into AD brains because the pathology is so diffuse—there are even plaques in the hypothalamus. But Greg's interest in PD may be an earlier target, although there are concerns about the underlying premise that we might discuss.
Well, I know the literature can be contradictory, but the recent article in science by Monje et al., 2003 suggests that CNS inflammation blocks adult hippocampal neurogenesis….
Endogenous neurogenesis is reduced in multiple situations but its rate can be altered even in the inflamed environment.
Kirk and others, there is a table in a recent review by X. Zhao et al. (Research and Perspectives in Neurosciences, 2003) that lists some 30 variables moderating in-vivo proliferation and neurogenesis in adult hippocampus and olfactory bulb.
Likewise, Forest labs has just gotten approval for Memantine (a glutamate regulator) for palliative treatment.
Hi, Mahendra; what are you thinking about with regard to memantine? Do you think there might be effects on neurogenesis or other regenerative processes?
Hi, June; yes, there was a paper by Rakic and colleagues (Haydar, et al., 2000) which showed that glutamate had specific direct effect on stem cell proliferation.
Thanks, George. Interesting to know about the Rakic paper. I'll have to get the reference.
All, I am wondering if anyone has an opinion on SSRI inhibitors and their effect on stem cells.
Mahendra, would you care to comment (from your personal perspective as opposed to NIH's) about the migration of stem cell research to privately funded labs and offshore, because of the policies of the Bush Administration? Is it likely that this research can reach critical mass with the threat of retaliation from the Right lurking in the national background?
That's a hot potato, Dan!
Dan, excellent question…. Let's remember that Mahendra works for the NIH; we don't want him to get into trouble.
My dream is that that hot potato will go away once we understand the basis for the fantastic plasticity underlying reprogramming of the genome. We could then use almost any isogenic somatic cell from the patient.
This is a difficult question. On one hand, the technological expertise required to follow on is really best in the United States. However, the number of cell lines available here is small. I see really only collaborations being the best way to go forward in the current situation of rules and regulations. The biggest problem is really that people don't share results and that makes it hard to move fast.
Mahendra, I agree. Let's collaborate.
Collaborations and openness are very important.
Reprogramming: yes, another contentious topic. In a review, Liu et Rao point out exactly what Dr. Martin said. We need to understand the mechanisms, and there is data on this from work done in the cancer field.
Anyone wish to add further comments about the question raised by Dan?
I worry that privately funded research will result in important reagents and intellectual property getting into the hands of only a few parties.
I cannot emphasize collaborations enough. Look at the genome project and other large-scale attempts. They are simply impossible without pooling expertise and skills. June's worry is real. The patent landscape is quite depressing.
I agree with June. I think, however, we should move on to another major topic. Who has one to suggest?
Sorry for the previous glitch; my name is Franzef and I work on the immunology of neural stem cells (NSCs). To get back to my unfinished question…well, most human neural cell lines are beyond passage 10, which, as Mahendra mentioned in his introduction, might mean that they are transformed, so how should one get around this problem, if you want to see real biology and/or have a well-characterized system?
Hi, Franz. That's an important question. Basically, there are no stable human lines that one can get off the shelf. They must be harvested and carefully checked for karyotypic stability.
I'll comment: I've worked with both somatic and ES cells (as have many of you). Only ES are immortal and diploid. And, most importantly, all of us start in more or less the same place with ES cells—which is very much not true with somatic cells.
I think that there are two possibilities and both require going back to tissue. Either ES cells or harvested adult stem cells from fetal tissue or brain biopsies (temporal), characterizing them carefully and making sure results are repeatable.
So the question is the maintenance of genomic integrity of cultured cells?
Yes, absolutely. There are other issues as well—epigenetic modulation and alteration in cell surface properties.
Another point to consider: ES cells are immortal and diploid, but their karyotype varies over time in culture, also.
Franz, there will always be strong selection for cells with slight replicative advantages and these could result from minor or major genetic changes.
Both Joy and George make important points. The solution currently is to carefully monitor and discard abnormal cells. We need good pathologists.
George, I was trying to say that as well: With mouse ES, trisomies often arise because they divide faster. They have to be routinely karyotyped and recloned…same goes for HES.
So, an approach would be to test biology on a long-term culture and try to replicate the results in a "new" culture harvested from "fresh" tissue?
Absolutely, dead-on, Franz. We did this by making immortalized cell lines but went back and rechecked everything with primary cells. Many things change, others stay the same, and the trick is knowing which is which.
Can I change the topic to the issue of intervention, via stem cells, in Parkinson's disease? Who wishes to comment?
Stem cells are a viable therapy in Parkinson's disease. Just like islets in diabetes and skeletal muscle in heart disease. The issue in all of these has been a source of verifiable, usable cells.
Is there any way that we can all be working on the same neural stem cells—a common set of conditions, a common set of characteristics that are used to define the cells? This has a lot of relevance to Parkinson's disease—lots of variation in cells means lots of variation among labs. And, I might add, what good does it do if only one lab can get a technique to work?
This is a critical question in stem cells. We work with neurally differentiated murine ES cells, and transferring the technique between labs, even when using the same cells and reagents, is not trivial.
Hi, Jeanne. My strategy has been to try and define markers and characteristics of whichever population I work with so that other people can replicate the results. The publishing of techniques should then make it useful to all labs. The NIH realized this, Joy, and has tried, at least in the case of ES cells, to sponsor training courses.
Mahendra, we're offering an HES training course in a couple of weeks; we're teaching HES and NSC techniques in parallel. Is that a good idea, or does it distract the students?
I think it's useful to do both. Many techniques are similar conceptually, but differ in details.
Tell us more about your course.
It's one of the five or so NIH-sponsored (T15) human ES training courses. It's cosponsored by the CHOC in Orange county and the Burnham Institute in La Jolla. It will be April 13-22 in La Jolla. Phil Schwartz, Evan Snyder, Robin Wesselschmidt and I are directing it.
Make sure we post this on the Alzforum calendar. We are starting to develop a Web page for the Alzforum on NS cells. The idea is to have a central information resource where essential data about different cell lines and methods can be posted. We're inviting input from everyone with an interest in this area to contribute advice and data!
June, this is a great idea (website domain for ES cell findings and resources).
I agree about maybe a vote for the top 10 markers that we should commonly examine, but focusing on one cell line/type seems too restrictive until we can find one that works well. There will always be the arguments to work first with mouse or get to the crux of the issue with human cells.
Dear Greg, the marker issue thread is true and I think perhaps even microarrays with 50-100 genes might be a good way to go.
Sounds like a good plan. Regarding the Parkinson's disease question: Is everyone convinced that the stem cell transplantation of dopaminergic neurons was effective? As opposed to nonspecific effects of surgery, a lesion, etc.?
I agree with Joy. There is a large literature on injury-induced regeneration.
The Swedish groups have really good data on human transplants and correlating improvement with dopamine release.
Back to my question on PD. I was impressed by a paper by John Haycock et al. in J. Neurochem in which there was evidence that the dopaminergic neuropil is reasonably intact during aging, despite dopamine being diminished.
For Parkinson's disease: There is another strategy that may be exciting and that is delivery via stem cells or glial cells of molecules and growth factors.
Would someone now wish to switch to a new subtopic on neural or other stem cells?
What about the research of using the patient's own bone stem cells, assuming they will adapt to the injury at hand…and become neuron stem cells.
Do we really think that bone marrow stem cells become neurons?
Angela, earlier in this chat session, I was bemoaning the negative results of two Nature papers that tried this with ischemic myocardium.
The idea of hematopoietic stem cells (HSCs) is seductive. They are already used for therapy, they are an autologous source, and there has been tantalizing evidence of transdifferentiation. However, as George pointed out, the numbers are not great.
However, it is possible to consider them as sources of growth factors—a rich source that may be useful.
Mahendra, back to the array issue. Is there some way to poll workers in the field so that everyone's favorite marker will arrive in a consensus array, made available to all?
Regarding array: Yes, the array people have formed consortia for this purpose and some private companies are trying to make focused arrays available cheaply. It's like information; I think if sufficient numbers of reagents are available, people will choose the best one and converge on a standard. We cannot mandate it.
How about fusion of transplanted cells?
What about human umbilical cord blood as an alternative source???
I've heard that umbilical cord has too few cells for anything but restoring blood cells. Am I right?
The immune issues for cord blood remain unresolved and the companies apparently don't find it a profitable market. New York and Duke are the two active cord blood banks available.
Well, actually, there is a company right here in Tampa, Florida.
I've heard that astrocytes can be induced to transform to a neuronal phenotype. Mahendra, can you comment?
Transdifferentiation: The problem is numbers, reliability, and heritability. If you transdifferentiate, will it stay transdifferentiated?
Back to Dr. Rao's topic of other roles for stem cells and relevant to the astrocyte question. Given the issues surrounding making new functional neurons, stem cells as a source of growth factors are a possibility, or what about using stem cells differentiated into astrocytes or microglia to promote clearance of Aβ?
Joy, I think this is a good idea and an example of thinking outside of the box, while most researchers in the field have fallen into it.
Regarding astrocytes and markers: Isn't it that neural stem cells express GFAP, and that we're finding more and more "differentiated" markers in pluripotent cells? We could use stem cells to target plaques because of the inflammation—and have them deliver an Aβ cleaving enzyme like neprilysin. Ideas?
Dear Jeanne, there is also data, particularly from Steindler's group (Laywell, et al., 2000), about authentic astrocytes dedifferentiating into stem cells and independent work from Martin Raff on glial progenitors Kondo and Raff, 2000. While I am not a fan of transdifferentiation on a practical level, I have to give credence to the published work from solid labs.
Jeanne, cultures of pluripotent cells may include mixtures of cells in various stages of differentiation.
George, I think "may" is inaccurate—always do, I think.
To follow up on George's comment: Does anybody know of any experiments where pure stem cell populations have been transplanted into the brain as opposed to a mixture?
What's pure? FACS-sorted? I think the NT2s are the closest anyone's done.
I agree with Jeanne, which suggests to me at least a major lacuna in our studies.
I've heard some scientists suggest (a few years ago) that if you transplant undifferentiated NS cells into an injured brain, the cells will migrate to the injury site and differentiate into the appropriate cell type(s) and become functional. Others advocate making the correct cell type in vitro and then transplanting. Does the weight of evidence currently favor one approach over the other as being more likely to succeed?
Dr. Rao, while waiting for an answer, I want to bring up the dangers of using feeder layers from other species or even from different individuals when trying to maintain stem cells in culture (i.e., viral transfer and viral recombinations).
Helen Blau and colleagues from Stanford University injected bone marrow from adult mice that express a marker called green fluorescent protein (GFP) into adult mice that had been irradiated to eliminate their bone marrow. They found that bone marrow-derived cells migrated into several regions of the brain, including the olfactory bulb, the cortex, the hippocampus, and the cerebellum (see LaBarge and Blau, 2002). Some of the marrow-derived neuronal cells also grew long fibers and produced a protein that indicates cell activity. These results suggest that the marrow-derived neurons not only entered the brain, but also responded to their environment and began to function like the native ones. They are not pure but they migrated there.
Dear Angela, see the fusion results from the same lab (Weiman et al.).
Would "pure" stem cells necessarily be better? Less differentiated cells can make their own support cells, vasculature, etc. Of course, they can also have unregulated growth.
I have to go. Send me e-mail if you'd like to continue this very interesting discussion offline. Or even better, perhaps we can all get together at Neuroscience in San Diego.
Feeders and xenocells: I think they are a clear concern, as is fetal bovine serum. However, the FDA has allowed xeno-organ transplants and perhaps they know more than we do.
I want to thank ALL of the participants, and especially Dr. Rao for this chat session.
Thanks for an interesting discussion.
A round of applause for Mahendra and George. CLAP CLAP CLAP!!
Thanks and bye.
By Mahendra Rao, National Institutes of Health, Baltimore, Maryland.
As we age, the brain's capacity gradually declines. This is associated with age-related changes in the brain environment, including elevated oxidative stress and the accumulation of protein and lipid byproducts and other mitochondrial changes. There is also a progressive reduction in synaptic function and a reduction in the total number of postmitotic cells, accompanied probably by a relative gliosis (Rosenzweig et al., 2003; Miller et al., 2003). At the same time, fewer new neurons are generated in the two major neurogenic regions—the subventricular zone (SVZ) surrounding the lateral ventricles, and the subgranular layer (SGL) of the hippocampal dentate gyrus (see Kempermann et al., 2002; Jessberger and Kempermann, 2003; Shors et al., 2002; Haughey et al., 2002). The underlying cause of this declining neurogenesis is unknown, but presumably it is related to the age-related changes that occur during normal aging of the brain.
Neurodegenerative diseases such as Alzheimer's and Parkinson's may well exacerbate these age-related changes in stem cell biology, and several studies indeed suggest as much (Haughey et al., 2002; Wen et al., 2002; Feng et al., 2002). It is important to note, however, that it is unclear at this early stage what's behind this decline (see for example Jin et al., 2004). Does it reflect a reduction in absolute numbers of stem cells, a failure of stem cells to respond to cues as they mature, a decline in proliferation cues, or even defects in the migration, survival, or integration of newborn neurons? It has been difficult to separate these issues as markers delineating stem cell stages are limited, and the quantifying overall number remains a challenge in spite of advances in stereologic methods.
It is in this context that one can examine the utility of stem cell therapy and perhaps generalize to other complex degenerative disorders. I believe there are three general ways of examining how cells can be used for therapy. Whichever one pursues, I believe that taking into consideration the cellular, molecular, and environmental changes of the aging brain will be critical. One can imagine replacing stem cells in the brain so that they replenish the reservoir. One can imagine mobilizing endogenous stem cells. Or one can imagine providing trophic support to either stem or differentiated cells using any population of cells that can survive with minimal damage to the brain parenchyma. Each of these strategies has its own problems that need to be considered when assessing potential therapeutic approaches. I summarize these below:
1. Replacement of Stem Cells
- Can only work where a stem cell niche exists: Most brain regions are devoid of stem cells that respond in any significant fashion after injury or in disease.
- Surgical approach to such a niche is difficult.
- The number of stem cells present in the adult human brain is vanishingly small (Roy et al., 2000; Nunes et al., 2003).
- Adult neural stem cells do not passage well and reports suggest that cells may be transformed in as little as 10 passages (Kim and Morshead, 2003).
- Fetal stem cells themselves do not survive if placed outside the stem cell niche and, in injury models, do not differentiate into neurons (personal observation).
- Positional information ("where do I belong?") appears relatively fixed and maintained in culture (Fishell et al., 1990; Parmar et al., 2002, and references therein).
- Use ES cell-derived neural derivatives to avoid the positional limitation.
- Figure out a way to alter positional identity.
- Learn to amplify stem cells in culture.
- Use differentiated cells that have the appropriate positional identity.
- Characterize stem cells better to enhance their survival in injury and bias differentiation appropriately.
2. Mobilization of Endogenous Cells:
In principle, this is much easier. Note, however, the caveat that one can only mobilize in regions where stem cells and cues exist to direct the cells' appropriate migration, differentiation, and integration. One can enhance or modulate an existing process, but cannot graft on an entirely new pathway of differentiation with any reasonable fidelity or chance of success in the near future.
- Can potentially be done in hippocampus and olfactory bulb, and possibly in the striatum (the presence of striatal stem cells is controversial; see, however, Kovacs et al., 2001; Chmielnicki et al., 2004).
- Noninvasive methods exist: exercise, hormones, calorie restriction, antioxidants, etc. (reviewed in Lie et al., 2004).
- Growth factors and possibly their small-molecule mimics can alter cell proliferation rate as much as 10-fold.
- The number of stem cells relative to the number of lost neurons is very small. Estimates from FACS sorting data suggest approximately 30,000 stem cells in the adult human brain (Goldman SA personal communication).
- The ongoing rate of division is very low; even a 10-fold increase is possibly two orders of magnitude less than what is required.
- The time to integration and maturation in humans is very slow.
- Despite increases in stem cell proliferation, the total increase in integration is small and many of the new neurons born die by apoptosis.
- Can this ever be enough given the massive loss in forebrain and other brain regions?
3. Enhance survival of existing neurons or delay death
Not novel, this idea is the basis for many current therapies in the nervous system. The problem here—and the reason why clinical trials have failed—has always been how to deliver trophic factors, or other molecules, across the blood-brain barrier and to the target site in sufficient levels without side effects due to unacceptable levels in other regions of the brain.
- Preliminary results in other models are encouraging (reviewed in Grondin et al., 2004). The requirement for cells is simpler: All they have to do is survive and remain within a given region. Success does not depend on 100 percent survival; a small increase in absolute numbers is sufficient and more achievable.
- Stem cells may not be ideal delivery vehicles for survival factors, as they may differentiate and integrate ectopically. Designed to proliferate or become quiescent, stem cells generally lack extensive secretory machinery.
- Stem cells require specialized niches to survive and will likely die in a diseased non-niche environment.
- Mesenchymal and other non-neural cells do not appear to last well in the environment; if they transdifferentiate, they do so at such a small frequency that it is not useful (reviewed in Liu et al 2003).
- Localized surgical delivery of cells remains necessary to achieve reasonable numbers. Even if intravenous infusion worked, the numbers are simply insufficient. Current data on intravenous infusion leading to homing to an appropriate site remain conceptually difficult to understand or wrong.
On Choice of Cell:
- Possibilities for delivery include glial cells of the CNS, Schwann cells, olfactory ensheathing cells, possibly mesenchymal cells, or microglia. Any of these cell types can be obtained in large numbers from fetal and adult sources. Constituting 90 percent of brain cells, glia generally provide trophic support, and as such, would be performing a function close to their physiological role.
- Mesenchymal cells have the advantage of potential autologous therapy and can be obtained in truly large numbers.
In conclusion, possibilities for stem cell therapies in neurodegenerative diseases remain encouraging. That said, important questions need to be answered before we can to predict which strategy will be appropriate for which disease. No one-size-fits-all cell therapy approach exists. If we are to reduce the tantalizing but highly variable data currently in the literature into an effective future therapy, I recommend that we focus on testing specific hypotheses of how cells may be effective, but do so with detailed, rigorous quantification.
Miller DB, O'Callaghan JP. Effects of aging and stress on hippocampal structure and function.
Metabolism. 2003 Oct;52(10 Suppl 2):17-21. Review. Abstract
Rosenzweig ES, Barnes CA. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog Neurobiol. 2003 Feb;69(3):143-79. Review. Abstract
Jessberger S, Kempermann G. Adult-born hippocampal neurons mature into activity-dependent responsiveness. Eur J Neurosci. 2003 Nov;18(10):2707-12. Abstract
Shors TJ, Townsend DA, Zhao M, Kozorovitskiy Y, Gould E. Neurogenesis may relate to some but not all types of hippocampal-dependent learning. Hippocampus. 2002;12(5):578-84. Abstract
Kempermann G, Gast D, Gage FH. Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol. 2002 Aug;52(2):135-43. Abstract
Wen PH, Shao X, Shao Z, Hof PR, Wisniewski T, Kelley K, Friedrich VL Jr, Ho L, Pasinetti GM, Shioi J, Robakis NK, Elder GA. Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis. 2002 Jun;10(1):8-19. Abstract
Wen PH, Friedrich VL Jr, Shioi J, Robakis NK, Elder GA. Presenilin-1 is expressed in neural progenitor cells in the hippocampus of adult mice. Neurosci Lett. 2002 Jan 25;318(2):53-6. Abstract
Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, Sopher B, Miller MW, Ware CB, Martin GM, Kim SH, Langdon RB, Sisodia SS, Tsien JZ. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces.
Neuron. 2001 Dec 6;32(5):911-26. Erratum in: Neuron 2002 Jan 17;33(2):313. Abstract
Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):343-7. Epub 2003 Dec 05. Abstract
Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann G 2nd, Jiang L, Kang J, Nedergaard M, Goldman SA. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med. 2003 Apr;9(4):439-47. Epub 2003 Mar 10. Abstract
Chmielnicki E, Goldman SA. Induced neurogenesis by endogenous progenitor cells in the adult mammalian brain. Prog Brain Res. 2002;138:451-64. Review. No abstract available. Abstract
Roy NS, Wang S, Jiang L, Kang J, Benraiss A, Harrison-Restelli C, Fraser RA, Couldwell WT, Kawaguchi A, Okano H, Nedergaard M, Goldman SA. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat Med. 2000 Mar;6(3):271-7. Abstract
Kim M, Morshead CM. Distinct populations of forebrain neural stem and progenitor cells can be isolated using side-population analysis. J Neurosci. 2003 Nov 19;23(33):10703-9. Abstract
Fishell G, Rossant J, van der Kooy D. Neuronal lineages in chimeric mouse forebrain are segregated between compartments and in the rostrocaudal and radial planes. Dev Biol. 1990 Sep;141(1):70-83. Abstract
Parmar M, Skogh C, Bjorklund A, Campbell K. Regional specification of neurosphere cultures derived from subregions of the embryonic telencephalon. Mol Cell Neurosci. 2002 Dec;21(4):645-56. Abstract
Kovacs AD, Cebers G, Cebere A, Moreira T, Liljequist S. Cortical and striatal neuronal cultures of the same embryonic origin show intrinsic differences in glutamate receptor expression and vulnerability to excitotoxicity. Exp Neurol. 2001 Mar;168(1):47-62. Abstract
Chmielnicki E, Benraiss A, Economides AN, Goldman SA. Adenovirally expressed noggin and brain-derived neurotrophic factor cooperate to induce new medium spiny neurons from resident progenitor cells in the adult striatal ventricular zone. J Neurosci. 2004 Mar 3;24(9):2133-42. Abstract
Schaffer DV, Gage FH. Neurogenesis and neuroadaptation. Neuromolecular Med. 2004;5(1):1-10. Abstract
Farmer J, Zhao X, Van Praag H, Wodtke K, Gage FH, Christie BR Effects of voluntary exercise on synaptic plasticity and gene expression in the dentate gyrus of adult male Sprague-Dawley rats in vivo. Neuroscience. 2004;124(1):71-9. Abstract
Lie DC, Song H, Colamarino SA, Ming GL, Gage FH. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol. 2004;44:399-421. Abstract
Grondin R, Zhang Z, Ai Y, Gash DM, Gerhardt GA. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog Drug Res. 2003;61:101-23. Review. Abstract
Liu Y, Rao MS. Transdifferentiation--fact or artifact. J Cell Biochem. 2003 Jan 1;88(1):29-40. Review. Abstract
Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. J Neurochem. 2002 Dec;83(6):1509-24. Abstract
- Rosenzweig ES, Barnes CA. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog Neurobiol. 2003 Feb;69(3):143-79. PubMed.
- Miller DB, O'Callaghan JP. Effects of aging and stress on hippocampal structure and function. Metabolism. 2003 Oct;52(10 Suppl 2):17-21. PubMed.
- Kempermann G, Gast D, Gage FH. Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol. 2002 Aug;52(2):135-43. PubMed.
- Jessberger S, Kempermann G. Adult-born hippocampal neurons mature into activity-dependent responsiveness. Eur J Neurosci. 2003 Nov;18(10):2707-12. PubMed.
- Shors TJ, Townsend DA, Zhao M, Kozorovitskiy Y, Gould E. Neurogenesis may relate to some but not all types of hippocampal-dependent learning. Hippocampus. 2002;12(5):578-84. PubMed.
- Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem. 2002 Dec;83(6):1509-24. PubMed.
- Wen PH, Friedrich VL, Shioi J, Robakis NK, Elder GA. Presenilin-1 is expressed in neural progenitor cells in the hippocampus of adult mice. Neurosci Lett. 2002 Jan 25;318(2):53-6. PubMed.
- Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, Sopher B, Miller MW, Ware CB, Martin GM, Kim SH, Langdon RB, Sisodia SS, Tsien JZ. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 2001 Dec 6;32(5):911-26. PubMed.
- Roy NS, Wang S, Jiang L, Kang J, Benraiss A, Harrison-Restelli C, Fraser RA, Couldwell WT, Kawaguchi A, Okano H, Nedergaard M, Goldman SA. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat Med. 2000 Mar;6(3):271-7. PubMed.
- Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann G, Jiang L, Kang J, Nedergaard M, Goldman SA. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med. 2003 Apr;9(4):439-47. PubMed.
- Kim M, Morshead CM. Distinct populations of forebrain neural stem and progenitor cells can be isolated using side-population analysis. J Neurosci. 2003 Nov 19;23(33):10703-9. PubMed.
- Fishell G, Rossant J, van der Kooy D. Neuronal lineages in chimeric mouse forebrain are segregated between compartments and in the rostrocaudal and radial planes. Dev Biol. 1990 Sep;141(1):70-83. PubMed.
- Parmar M, Skogh C, Björklund A, Campbell K. Regional specification of neurosphere cultures derived from subregions of the embryonic telencephalon. Mol Cell Neurosci. 2002 Dec;21(4):645-56. PubMed.
- Kovács AD, Cebers G, Cebere A, Moreira T, Liljequist S. Cortical and striatal neuronal cultures of the same embryonic origin show intrinsic differences in glutamate receptor expression and vulnerability to excitotoxicity. Exp Neurol. 2001 Mar;168(1):47-62. PubMed.
- Chmielnicki E, Benraiss A, Economides AN, Goldman SA. Adenovirally expressed noggin and brain-derived neurotrophic factor cooperate to induce new medium spiny neurons from resident progenitor cells in the adult striatal ventricular zone. J Neurosci. 2004 Mar 3;24(9):2133-42. PubMed.
- Lie DC, Song H, Colamarino SA, Ming GL, Gage FH. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol. 2004;44:399-421. PubMed.
- Grondin R, Zhang Z, Ai Y, Gash DM, Gerhardt GA. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog Drug Res. 2003;61:101-23. PubMed.
- Liu Y, Rao MS. Transdifferentiation--fact or artifact. J Cell Biochem. 2003 Jan 1;88(1):29-40. PubMed.
- Wen PH, Shao X, Shao Z, Hof PR, Wisniewski T, Kelley K, Friedrich VL, Ho L, Pasinetti GM, Shioi J, Robakis NK, Elder GA. Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis. 2002 Jun;10(1):8-19. PubMed.
- Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):343-7. PubMed.
- Chmielnicki E, Goldman SA. Induced neurogenesis by endogenous progenitor cells in the adult mammalian brain. Prog Brain Res. 2002;138:451-64. PubMed.
- Schaffer DV, Gage FH. Neurogenesis and neuroadaptation. Neuromolecular Med. 2004;5(1):1-9. PubMed.
- Farmer J, Zhao X, van Praag H, Wodtke K, Gage FH, Christie BR. Effects of voluntary exercise on synaptic plasticity and gene expression in the dentate gyrus of adult male Sprague-Dawley rats in vivo. Neuroscience. 2004;124(1):71-9. PubMed.
- Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004 Apr 8;428(6983):664-8. PubMed.
- Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004 Apr 8;428(6983):668-73. PubMed.
- Freed CR, Leehey MA, Zawada M, Bjugstad K, Thompson L, Breeze RE. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation?. J Neurol. 2003 Oct;250 Suppl 3:III44-6. PubMed.
- Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003 Dec 5;302(5651):1760-5. PubMed.
- Haydar TF, Wang F, Schwartz ML, Rakic P. Differential modulation of proliferation in the neocortical ventricular and subventricular zones. J Neurosci. 2000 Aug 1;20(15):5764-74. PubMed.
- Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, Kish SJ. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem. 2003 Nov;87(3):574-85. PubMed.
- Laywell ED, Rakic P, Kukekov VG, Holland EC, Steindler DA. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13883-8. PubMed.
- Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science. 2000 Sep 8;289(5485):1754-7. PubMed.
- LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell. 2002 Nov 15;111(4):589-601. PubMed.
- Weimann JM, Johansson CB, Trejo A, Blau HM. Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant. Nat Cell Biol. 2003 Nov;5(11):959-66. PubMed.
- Song H, Ming G, He Z, Lehmann M, McKerracher L, Tessier-Lavigne M, Poo M. Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides. Science. 1998 Sep 4;281(5382):1515-8. PubMed.
- Caroni P. Driving the growth cone. Science. 1998 Sep 4;281(5382):1465-6. PubMed.